KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Inventory (2017 - 2025)

Amneal Pharmaceuticals has reported Inventory over the past 9 years, most recently at $606.3 million for Q4 2025.

  • Quarterly results put Inventory at $606.3 million for Q4 2025, down 1.0% from a year ago — trailing twelve months through Dec 2025 was $606.3 million (down 1.0% YoY), and the annual figure for FY2025 was $606.3 million, down 1.0%.
  • Inventory for Q4 2025 was $606.3 million at Amneal Pharmaceuticals, down from $614.5 million in the prior quarter.
  • Over the last five years, Inventory for AMRX hit a ceiling of $614.5 million in Q3 2025 and a floor of $489.4 million in Q4 2021.
  • Median Inventory over the past 5 years was $560.6 million (2023), compared with a mean of $558.7 million.
  • Biggest five-year swings in Inventory: rose 17.89% in 2021 and later dropped 1.0% in 2025.
  • Amneal Pharmaceuticals' Inventory stood at $489.4 million in 2021, then grew by 8.45% to $530.7 million in 2022, then increased by 9.54% to $581.4 million in 2023, then grew by 5.34% to $612.5 million in 2024, then decreased by 1.0% to $606.3 million in 2025.
  • The last three reported values for Inventory were $606.3 million (Q4 2025), $614.5 million (Q3 2025), and $609.0 million (Q2 2025) per Business Quant data.